<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911183</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000636032</org_study_id>
    <secondary_id>IB-FRAIL06</secondary_id>
    <secondary_id>INCA-RECF0892</secondary_id>
    <secondary_id>IB-2008-25</secondary_id>
    <secondary_id>EUDRACT-2008-001506-16</secondary_id>
    <nct_id>NCT00911183</nct_id>
  </id_info>
  <brief_title>Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such&#xD;
      as cyclophosphamide, vincristine sulfate, prednisone, and liposome-encapsulated doxorubicin&#xD;
      citrate, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or by stopping them from dividing. It is not yet known whether rituximab and&#xD;
      combination chemotherapy are more effective when given together with or without&#xD;
      liposome-encapsulated doxorubicin citrate in treating older patients with diffuse large&#xD;
      B-cell non-Hodgkin lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying the side effects of giving rituximab&#xD;
      together with cyclophosphamide, vincristine sulfate, and prednisone with or without&#xD;
      liposome-encapsulated doxorubicin citrate and to see how well it works in treating older&#xD;
      patients with stage II, stage III, or stage IV diffuse large B-cell non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the therapeutic efficacy of rituximab, cyclophosphamide, vincristine sulfate,&#xD;
           and prednisone with vs without liposome-encapsulated doxorubicin citrate, in terms of&#xD;
           complete remission rate at 6 months, in vulnerable or frail elderly patients with stage&#xD;
           II, III, or IV diffuse large B-cell non-Hodgkin lymphoma.&#xD;
&#xD;
        -  To assess the safety of these regimens in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the progression-free survival, event-free survival, and overall survival&#xD;
           rates at 6 and 24 months in patients treated with these regimens.&#xD;
&#xD;
        -  To evaluate the overall response rate at 6 and 24 months in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  To evaluate the duration of complete remission in patients treated with these regimens.&#xD;
&#xD;
        -  To evaluate the acute side effects (according to the International CTC scale) of these&#xD;
           regimens in these patients.&#xD;
&#xD;
        -  To evaluate the geriatric condition and quality of life of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (R-COP regimen): Patients receive rituximab IV, cyclophosphamide IV, and&#xD;
           vincristine sulfate IV on day 1. Patients also receive oral prednisone on days 1-5 and&#xD;
           filgrastim subcutaneously (SC) on days 8-14 or pegfilgrastim SC on day 2. Treatment&#xD;
           repeats every 21 days for at least 3 courses.&#xD;
&#xD;
        -  Arm II (R-COPY regimen): Patients receive rituximab, cyclophosphamide, vincristine&#xD;
           sulfate, prednisone, and filgrastim or pegfilgrastim as in arm I. Patients also receive&#xD;
           liposome-encapsulated doxorubicin citrate IV on day 1. Treatment repeats every 21 days&#xD;
           for at least 3 courses.&#xD;
&#xD;
      After 3 courses of R-COP or R-COPY, patients undergo evaluation. Patients with disease&#xD;
      progression or a response of &lt; 25% are removed from the study. Patients with a response of ≥&#xD;
      25% receive 3 more courses of R-COP or R-COPY, followed by rituximab IV alone on day 1 of&#xD;
      courses 7 and 8 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After the completion of chemotherapy, some patients may undergo radiotherapy.&#xD;
&#xD;
      Patients complete quality of life and geriatric assessment questionnaires at baseline and&#xD;
      periodically during study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 6&#xD;
      months for 2 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate at 6 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, event-free survival, and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete remission</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute side effects as assessed by the International CTC scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric condition as assessed by the following questionnaires: the Cumulative Illness Rating Scale-Geriatric, the Mini Nutritional Assessment, the Instrumental Activities of Daily Living, the QLQ-C30, the Mini Mental State Examination, and the Geri ...</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (R-COP regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV, cyclophosphamide IV, and vincristine sulfate IV on day 1. Patients also receive oral prednisone on days 1-5 and filgrastim subcutaneously (SC) on days 8-14 or pegfilgrastim SC on day 2. Treatment repeats every 21 days for at least 3 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (R-COPY regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab, cyclophosphamide, vincristine sulfate, prednisone, and filgrastim or pegfilgrastim as in arm I. Patients also receive liposome-encapsulated doxorubicin citrate IV on day 1. Treatment repeats every 21 days for at least 3 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I (R-COP regimen)</arm_group_label>
    <arm_group_label>Arm II (R-COPY regimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I (R-COP regimen)</arm_group_label>
    <arm_group_label>Arm II (R-COPY regimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (R-COP regimen)</arm_group_label>
    <arm_group_label>Arm II (R-COPY regimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (R-COP regimen)</arm_group_label>
    <arm_group_label>Arm II (R-COPY regimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposome-encapsulated doxorubicin citrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (R-COPY regimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (R-COP regimen)</arm_group_label>
    <arm_group_label>Arm II (R-COPY regimen)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (R-COP regimen)</arm_group_label>
    <arm_group_label>Arm II (R-COPY regimen)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of diffuse large B-cell non-Hodgkin lymphoma&#xD;
&#xD;
               -  Stage II, III, or IV disease (according to the WHO classification), including all&#xD;
                  morphological and clinical variants&#xD;
&#xD;
                    -  No Burkitt-like lymphoma (presence of small cells in the bone marrow biopsy&#xD;
                       allowed)&#xD;
&#xD;
               -  CD20+ disease&#xD;
&#xD;
          -  Has ≥ 1 measurable target lesion ≥ 1.1 cm (according to the International Workshop&#xD;
             Criteria)&#xD;
&#xD;
          -  Poor physiological status, as defined by ≥ 1 of the following criteria:&#xD;
&#xD;
               -  WHO performance status 3&#xD;
&#xD;
               -  Clinical evaluation and measurement of LVEF that would preclude doxorubicin&#xD;
                  administration (i.e., LVEF &lt; 50%)&#xD;
&#xD;
               -  Creatinine clearance &lt; 50 mL/min&#xD;
&#xD;
               -  Serum bilirubin &gt; 30 μmol/L&#xD;
&#xD;
               -  Severe comorbidity that would preclude the use of CHOP chemotherapy&#xD;
&#xD;
          -  Ineligible for standard R-CHOP therapy&#xD;
&#xD;
          -  No cerebral or meningeal involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-3&#xD;
&#xD;
          -  ANC &gt; 750/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm^3&#xD;
&#xD;
          -  LVEF &gt; 35%&#xD;
&#xD;
          -  Able to receive either R-COP or R-COPY therapy&#xD;
&#xD;
          -  No congestive heart failure, serious arrhythmia, or myocardial infarction within the&#xD;
             past 6 months&#xD;
&#xD;
          -  No other malignancy within the past 5 years except for adequately treated basal cell&#xD;
             carcinoma of the skin or curatively treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No active viral hepatitis B or C by serology&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No hypersensitivity to rituximab, any of its excipients, or to murine proteins&#xD;
&#xD;
          -  No documented history of allergy to eggs or egg products&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude compliance with study treatment or follow-up schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior therapy for this cancer&#xD;
&#xD;
          -  No prior anthracycline administration with a cumulative dose &gt; 240 mg/m² of&#xD;
             doxorubicin hydrochloride or &gt; 400 mg/m² of epirubicin hydrochloride&#xD;
&#xD;
          -  More than 30 days since prior participation in another clinical trial involving&#xD;
             investigational drugs&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Soubeyran, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Soubeyran, MD, PhD</last_name>
      <phone>33-556-333-267</phone>
      <email>soubeyran_p@bergonie.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>May 29, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2009</study_first_posted>
  <last_update_submitted>July 21, 2009</last_update_submitted>
  <last_update_submitted_qc>July 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2009</last_update_posted>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 29, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

